Article Sidebar

PDF
Issue: No. 44 (2021)
Section: Article
Date Published: 25/12/2021
Views 10
Downloads 2
How to Cite
Huynh, M. D., Le, T. V., Pham, H. M. Q., Le, H. P., Lam, V. H., & Duong, L. T. T. (2021). EFFECTIVE TREATMENT OF ADVANCED - STAGE NON SMALL LUNG CELL CANCER WITH EGFR MUTATIONS: A CLINICAL CASE AND OVERVIEW OF TREATMENT. Cantho Journal of Medicine and Pharmacy, 44, 159-170. https://tapchi.ctump.edu.vn/index.php/ctump/article/view/1058

EFFECTIVE TREATMENT OF ADVANCED - STAGE NON SMALL LUNG CELL CANCER WITH EGFR MUTATIONS: A CLINICAL CASE AND OVERVIEW OF TREATMENT

Minh Dong Huynh1, , Thanh Vu Le1, Hoang Minh Quan Pham1, Hoang Phuc Le1, Vinh Hao Lam1, Le Tan Truong Duong1
1 Can Tho University of Medicine and Pharmacy Hospital

Main Article Content

Abstract

Background: In recent years, therapy for lung cancer treatment have been developing rapidly, with many new molecular targets in the treatment of lung cancer have been discovered such as EGFR, ROS1, KRAS, ALK, PD-L1...which help to prolong patients’ survival time and and improve patient's quality of their life. Of those Tyrosine Kinase Inhibitors (TKIs) of the Epithelial Growth Factor Receptor (EGFR) have been extensively studied and used for cancer patients nationwide and worldwide. Patients with Non-Small Cell Lung Cancer (NSCLC) harboring this EGFR mutation usually show an effective response to the targeted therapy. In clinical trials, the use of targeted drugs resulted in statistically significantly higher progression-free survival (PFS) compared with chemotherapy. In addition, the level of safety of the drugs has also been proved to be higher, overcoming the limitations of using chemical drugs such as the lack of specific selectivity for each individual and many side effects affecting the treatment cylce as well as it is effectiveness with chemotherapy. Case report: A 65-year-old female patient diagnosed with advanced - stage lung adenocarcinoma, having brain and pleural metastases, who habours the L858R point mutation of the EGFR gene. The patient was treated with Gefitinib and underwent Gamma Knife Radiosurgery, who is currently in partial response after 14 months of treatment and continues to be monitored for response to treatment. Conclusions: Treatment options for advanced stage non-small cell lung cancer depend on: Histopathologic type, EGFR mutation, patient's physical condition and economy.... Gefitinib is one of the effective target drugs in the first-line treatment for lung adenocarcinoma patients with EGFR gene mutations. It does improve the quality of patients’ life and prolongs survival time with low and acceptable toxicity.

Keywords

Non-small lung cell cancer, EGFR mutations, targeted therapy

Article Details

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

References

1. Bộ Y Tế (2018), Hướng dẫn chẩn đoán và điều trị ung thư phổi không tế bào nhỏ.
2. Huỳnh Quyết Thắng, Châu Phú Thi (2019), Điều trị ung thư phổi không tế bào nhỏ (từ trị liệu kinh điển đến miễn dịch liệu pháp). Nhà Xuất Bản Y Học, Hà Nội.
3. Anne S. Tsao (2015), Scientific Advances in Lung Cancer. Journal of Thoracic Oncology, Vol. 11, No 5.
4. Andrea Bertotti and Francesco Sassi (2015). Molecular Pathways: Sensitivity and Resistance to Anti-EGFR Antibodies. Clin Cancer Res, August 2015 vol 21, no 15, pp.3377-3383.
5. Bianco R, Gelardi T, Damiano V, Ciardiello F, Tortora G (2007), Rational Bases for the Development of EGFR Inhibitors for Cancer Treatment. The International Journal of Biochemistry & Cell Biology, vol 39, pp.1416–1431.
6. Carlo La Vecchia, Jyoti Malhotra, Matteo Malvezzi, Eva Negri, Paolo Boffetta (2016), Risk factors for lung cancer worldwide. European Respiratory Journal, vol 48, pp.889-902.
7. Chang A, Parikh P (2006), Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol, October, vol 1(8), pp.847-55.
8. D. Planchard, Popat S, Kerr K and et al (2018), Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29 (Supplement 4), iv192–iv237.
9. GLOBOCAN (2020), Etimated Cancer Incidence, Mortality and Prevalance Worldwide in 2020.
10. Hao Bai, Liwen Xiong, Baohui Han (2017), The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer. OncoTargets and Therapy journal, 27 April, Volume 2017, no 10, pp. 2335—2340.
11. Hee-Young Yoon, Jeong-Seon Ryu, Yun Su Sim, Dojin Kim and et al (2020), Clinical significance of EGFR mutation types in lung adenocarcinoma: A multi-centre Korean study. PLoS ONE, vol 15(2), e0228925.
12. Jackman DM, Stephanie Heon (2012), The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer with EGFR Mutations. Clin Cancer Res, August, vol 8: 18(16), pp.4406-4414.
13. Kim ES, Hirsch V (2008), Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet Oncol, vol 372, pp.1809-1818.
14. Meamondo M, Inoue A (2010), Gefitinib or chemotherapy for non-small cell lung cancer with mutated EGFR. N Engl J Med, vol 362, pp.2380-2388
15. Non - Small Cell Lung Cancer. NCCN Guidelines, Versions 3.2018, pp.17-32.
16. P.E. Postmus, K.M. Kerr, M. Oudkerk and et al (2017), Early and locally advanced nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Lung & chest tumours, volume 28, supplement 4, iv1-iv21.
17. Porta R, Sanchez-Torres J. M, Paz-Ares L and et al (2011), Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation, Eur Respir Journal, vol 37(3), pp.624-31.
18. Raffaele Costanzo, Maria Carmela Piccirillo, Claudia Sandomenico and et al (2011), Gefitinib in Non Small Cell Lung Cancer. BioMed Research International, vol 2011, Article 815269, pp.14.
19. Rosell R, Moran T, Queralt C and et al (2009), Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, Vol 361(10), p958–967.
20. Sullivan I. and Planchard D. (2017), Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line. Front Med, pp.1-3.
21. Yang L, Liu XY (2006), Gefitinib in the treatment of advanced nonsmall cell lung cancer, Zhonghua Zhong Liu ZaZhi, vol 28(6), pp.474-7.
22. Yarden Y (2001), The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer, vol 37, pp.3-8
23. Wang H, Huang J, Yu X and et al (2014), Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis. Journal of Cancer Research and Clinical Oncology, vol 140(11), pp.1901-1909.
24. Zhong WZ, Wang Q, Mao WM and et al (2018), Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1–N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol, vol 19, pp.139-48.